These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Further characterization of the effects of BMY 14802 on dopamine neuronal activity. Zhang J; Chiodo LA; Freeman AS Synapse; 1993 Dec; 15(4):276-84. PubMed ID: 7908761 [TBL] [Abstract][Full Text] [Related]
4. Supersensitivity of sigma receptors after repeated administration of cocaine. Ujike H; Tsuchida K; Akiyama K; Otsuki S Life Sci; 1992; 51(6):PL31-6. PubMed ID: 1353244 [TBL] [Abstract][Full Text] [Related]
5. BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine. Kanzaki A; Okumura K; Ujike H; Tsuchida K; Akiyama K; Otsuki S J Neural Transm Gen Sect; 1992; 90(2):137-44. PubMed ID: 1361127 [TBL] [Abstract][Full Text] [Related]
7. Neuroleptics with differential affinities at dopamine D2 receptors and sigma receptors affect differently the N-methyl-D-aspartate-induced increase in intracellular calcium concentration: involvement of protein kinase. Hayashi T; Su TP; Kagaya A; Nishida A; Shimizu M; Yamawaki S Synapse; 1999 Jan; 31(1):20-8. PubMed ID: 10025680 [TBL] [Abstract][Full Text] [Related]
8. The effects of sigma ligands on the release of glutamate from rat striatal slices. Ellis Y; Davies JA Naunyn Schmiedebergs Arch Pharmacol; 1994 Aug; 350(2):143-8. PubMed ID: 7990971 [TBL] [Abstract][Full Text] [Related]
10. Lack of functional evidence for the involvement of sigma opiate receptors in the actions of the 3-PPP enantiomers on central dopaminergic systems: discrepancies between in vitro and in vivo observations. Hjorth S; Clark D; Carlsson A Life Sci; 1985 Aug; 37(7):673-84. PubMed ID: 2410756 [TBL] [Abstract][Full Text] [Related]
11. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'-oxoethyl)- piperidine HBr], a sigma and 5-hydroxytryptamine2 receptor antagonist: receptor-binding, electrophysiological and neuropharmacological profiles. Tam SW; Steinfels GF; Gilligan PJ; Schmidt WK; Cook L J Pharmacol Exp Ther; 1992 Dec; 263(3):1167-74. PubMed ID: 1361572 [TBL] [Abstract][Full Text] [Related]
12. Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)piperidine (3-PPP). Further developments of a dopamine receptor model. Liljefors T; Bøgesø KP; Hyttel J; Wikström H; Svensson K; Carlsson A J Med Chem; 1990 Mar; 33(3):1015-22. PubMed ID: 1968512 [TBL] [Abstract][Full Text] [Related]
13. Heterocyclic amino alcohols related to ifenprodil as sigma receptor ligands: binding and conformational analyses. Beart PM; Ryan MC; Mercer LD; Jarrott B; Wong MG Eur J Pharmacol; 1994 Oct; 269(2):193-200. PubMed ID: 7851495 [TBL] [Abstract][Full Text] [Related]
14. N-substituted 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines and 3-phenylpiperidines: effects on central dopamine and sigma receptors. Wikström H; Andersson B; Elebring T; Svensson K; Carlsson A; Largent B J Med Chem; 1987 Dec; 30(12):2169-74. PubMed ID: 2824773 [TBL] [Abstract][Full Text] [Related]
15. The behavioural effects of pramipexole, a novel dopamine receptor agonist. Maj J; Rogóz Z; Skuza G; Kołodziejczyk K Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910 [TBL] [Abstract][Full Text] [Related]
16. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats. Ekman A; Quiding M; Eriksson E Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291 [TBL] [Abstract][Full Text] [Related]